Investing.com - Magenta Therapeutics (NASDAQ: MGTA) reported third quarter EPS of $-0.05, in line with the analyst estimate of $-0.05. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Magenta Therapeutics's stock price closed at $0.76. It is up 7.34% in the last 3 months and down -60.62% in the last 12 months.
Magenta Therapeutics saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Magenta Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Magenta Therapeutics's Financial Health score is "fair performance".
Check out Magenta Therapeutics's recent earnings performance, and Magenta Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar